We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BillionToOne (BLLN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
BillionToOne is a member of the Medical sector. This group includes 884 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BillionToOne is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BLLN's full-year earnings has moved 612.8% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that BLLN has returned about 19.5% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 4.5% on average. As we can see, BillionToOne is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Eledon Pharmaceuticals, Inc. (ELDN - Free Report) . The stock is up 156.3% year-to-date.
The consensus estimate for Eledon Pharmaceuticals, Inc.'s current year EPS has increased 24.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, BillionToOne belongs to the Medical - Products industry, a group that includes 78 individual companies and currently sits at #170 in the Zacks Industry Rank. This group has lost an average of 24.1% so far this year, so BLLN is performing better in this area.
Eledon Pharmaceuticals, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 430-stock industry is ranked #146. The industry has moved +0.4% so far this year.
BillionToOne and Eledon Pharmaceuticals, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BillionToOne (BLLN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
BillionToOne is a member of the Medical sector. This group includes 884 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BillionToOne is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BLLN's full-year earnings has moved 612.8% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that BLLN has returned about 19.5% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 4.5% on average. As we can see, BillionToOne is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Eledon Pharmaceuticals, Inc. (ELDN - Free Report) . The stock is up 156.3% year-to-date.
The consensus estimate for Eledon Pharmaceuticals, Inc.'s current year EPS has increased 24.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, BillionToOne belongs to the Medical - Products industry, a group that includes 78 individual companies and currently sits at #170 in the Zacks Industry Rank. This group has lost an average of 24.1% so far this year, so BLLN is performing better in this area.
Eledon Pharmaceuticals, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 430-stock industry is ranked #146. The industry has moved +0.4% so far this year.
BillionToOne and Eledon Pharmaceuticals, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.